251 related articles for article (PubMed ID: 35257600)
21. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
Qu Y; Shurzinske L; Sethuraman S
Pharm Stat; 2021 Mar; 20(2):314-323. PubMed ID: 33098267
[TBL] [Abstract][Full Text] [Related]
22. Estimands: discussion points from the PSI estimands and sensitivity expert group.
Phillips A; Abellan-Andres J; Soren A; Bretz F; Fletcher C; France L; Garrett A; Harris R; Kjaer M; Keene O; Morgan D; O'Kelly M; Roger J
Pharm Stat; 2017 Jan; 16(1):6-11. PubMed ID: 26997517
[TBL] [Abstract][Full Text] [Related]
23. Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
Weir IR; Dufault SM; Phillips PP
Res Sq; 2023 Nov; ():. PubMed ID: 37986887
[TBL] [Abstract][Full Text] [Related]
24. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.
Ratitch B; Goel N; Mallinckrodt C; Bell J; Bartlett JW; Molenberghs G; Singh P; Lipkovich I; O'Kelly M
Ther Innov Regul Sci; 2020 Mar; 54(2):370-384. PubMed ID: 32072586
[TBL] [Abstract][Full Text] [Related]
25. Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
Qu Y; Lipkovich I
Ther Innov Regul Sci; 2021 Sep; 55(5):984-988. PubMed ID: 33983621
[TBL] [Abstract][Full Text] [Related]
26. The detailed clinical objectives approach to designing clinical trials and choosing estimands.
Bell J; Hamilton A; Sailer O; Voss F
Pharm Stat; 2021 Nov; 20(6):1112-1124. PubMed ID: 34013553
[TBL] [Abstract][Full Text] [Related]
27. Single-world intervention graphs for defining, identifying, and communicating estimands in clinical trials.
Ocampo A; Bather JR
Stat Med; 2023 Sep; 42(21):3892-3902. PubMed ID: 37340887
[TBL] [Abstract][Full Text] [Related]
28. Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.
Mallinckrodt CH; Bell J; Liu G; Ratitch B; O'Kelly M; Lipkovich I; Singh P; Xu L; Molenberghs G
Ther Innov Regul Sci; 2020 Mar; 54(2):353-364. PubMed ID: 32072593
[TBL] [Abstract][Full Text] [Related]
29. Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials.
Mehrotra DV; Hemmings RJ; Russek-Cohen E;
Clin Trials; 2016 Aug; 13(4):456-8. PubMed ID: 26908545
[TBL] [Abstract][Full Text] [Related]
30. Application of estimand framework in ICH E9 (R1) to safety evaluation.
Wang X; Yang P; Yuan SS; Wang WWB
J Biopharm Stat; 2023 Jul; 33(4):476-487. PubMed ID: 36951445
[TBL] [Abstract][Full Text] [Related]
31. Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.
Aroda VR; Saugstrup T; Buse JB; Donsmark M; Zacho J; Davies MJ
Diabetes Obes Metab; 2019 Oct; 21(10):2203-2210. PubMed ID: 31168921
[TBL] [Abstract][Full Text] [Related]
32. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Lawrance R; Degtyarev E; Griffiths P; Trask P; Lau H; D'Alessio D; Griebsch I; Wallenstein G; Cocks K; Rufibach K
J Patient Rep Outcomes; 2020 Aug; 4(1):68. PubMed ID: 32833083
[TBL] [Abstract][Full Text] [Related]
33. Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies.
Luijken K; van Eekelen R; Gardarsdottir H; Groenwold RHH; van Geloven N
Pharmacoepidemiol Drug Saf; 2023 Aug; 32(8):863-872. PubMed ID: 36946319
[TBL] [Abstract][Full Text] [Related]
34. Statistical methods for handling missing data to align with treatment policy strategy.
Wang Y; Tu W; Kim Y; Sinks S; He J; Cambon A; Crackel R; Hamilton K; Kettermann A; Clark J
Pharm Stat; 2023; 22(4):650-670. PubMed ID: 36970810
[TBL] [Abstract][Full Text] [Related]
35. Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
[TBL] [Abstract][Full Text] [Related]
36. Estimands for factorial trials.
Kahan BC; Morris TP; Goulão B; Carpenter J
Stat Med; 2022 Sep; 41(22):4299-4310. PubMed ID: 35751568
[TBL] [Abstract][Full Text] [Related]
37. Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
Casey M; Degtyarev E; Lechuga MJ; Aimone P; Ravaud A; Motzer RJ; Liu F; Stalbovskaya V; Tang R; Butler E; Sailer O; Halabi S; George D
Pharm Stat; 2021 Mar; 20(2):324-334. PubMed ID: 33155417
[TBL] [Abstract][Full Text] [Related]
38. Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
Bissonnette R; Eichenfield LF; Simpson E; Thaçi D; Kabashima K; Thyssen JP; Guttman-Yassky E; Nunes FP; Gamalo M; Ahmad F; Kuligowski M; Sun K; Pipper C; Christensen AW; D'Angelo P; Milutinovic M; Guettner A; Silverberg JI
J Eur Acad Dermatol Venereol; 2023 May; 37(5):976-983. PubMed ID: 36652273
[TBL] [Abstract][Full Text] [Related]
39. Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey.
Fletcher C; Tsuchiya S; Mehrotra DV
Ther Innov Regul Sci; 2017 Jan; 51(1):69-76. PubMed ID: 30236003
[TBL] [Abstract][Full Text] [Related]
40. The attributable estimand: A new approach to account for intercurrent events.
Darken P; Nyberg J; Ballal S; Wright D
Pharm Stat; 2020 Sep; 19(5):626-635. PubMed ID: 32198954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
